Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GenMark Diagnostics, Inc.GNMK · Entity 140086 | Director | April 22, 2021 | April 22, 2021 |
| HCW Biologics Inc.HCWB · Entity 8172 | Director | June 14, 2024 | June 17, 2024 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GenMark Diagnostics, Inc.
Report date April 22, 2021 · Filed April 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 1
1 source rowRow 1 · 2021-04-22 · Other · Disposed 81,572 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F2: Includes 21,607 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU. |
| Common StockSEC Table I · non-derivative | IndirectLisa M Giles Living Trust | 0 |
Reported balance
After 2021-04-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-04-22 · Other · Disposed 5,500 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F3: Ms. Giles is the trustee of the Lisa M Giles Living Trust and has voting and dispositive power with respect to these shares. Ms. Giles disclaims beneficial ownership except to the extent of her pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.17 · Expires 2025-02-19 | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-22 · Disposition to issuer · Disposed 19,062 · Balance 0 F4: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Includes 21,607 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU.
F3: Ms. Giles is the trustee of the Lisa M Giles Living Trust and has voting and dispositive power with respect to these shares. Ms. Giles disclaims beneficial ownership except to the extent of her pecuniary interest therein.
F4: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof.
HCW Biologics Inc.
Report date June 14, 2024 · Filed June 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2025-06-13 | Direct | 12,500 |
Reported balance
After 2024-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-14 · Grant · Acquired 12,500 · Balance 12,500 F1: (1) 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 13, 2025 or (b) the next annual meeting of stockholders, subject to the Reporting Person continuing to provide services through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 13, 2025 or (b) the next annual meeting of stockholders, subject to the Reporting Person continuing to provide services through the vesting date.
Milestone Pharmaceuticals Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10 | Direct | 77,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001568850-26-000002 · form4-06122026_040607.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:19 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001415889-25-016931 · form4-06122025_040608.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001415889-24-022534 · form4-08292024_040806.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-08-28 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on September 28, 2024, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 17:07 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000950170-24-074365 · ownership.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2025-06-13 F1 · derivative.exercise_date: (1) 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 13, 2025 or (b) the next annual meeting of stockholders, subject to the Reporting Person continuing to provide services through the vesting date. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 14:22 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantCommon Stock | 35,715 | $1.40 | $50,001.00 |
DisclosureSEC source: 0001209191-24-003785 · doc4.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,815 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 17:13 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-23-037420 · doc4.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-12 F1 · derivative.exercise_date: 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 13, 2024 or (b) the next annual meeting of stockholders, subject to the Reporting Person continuing to provide services through the vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:21 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001209191-23-035836 · doc4.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 7, 2023, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| July 05, 2022 Filed Aug 11, 2022 22:01 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001209191-22-045471 · doc4.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2032-07-05 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on August 5, 2022, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:18 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 41,841 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001209191-22-037849 · doc4.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,841 Underlying: Common Stock · 41,841 shares Expires 2032-06-14 F1 · derivative.exercise_date: 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 15, 2023 or (b) the next annual meeting of stockholders, subject to the Reporting Person continuing to provide services through the vesting date. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 17:12 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option · Derivative | 37,037 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-21-061922 · doc4.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,037 Underlying: Common Stock · 37,037 shares Expires 2031-10-25 F1 · derivative.exercise_date: The option will fully vest on October 26, 2022. Read SEC document |
| June 14, 2021 Filed Jul 29, 2021 21:35 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-21-048565 · doc4.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 14, 2021, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| April 22, 2021 Filed Apr 22, 2021 13:55 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,062 | Not disclosed Strike: $13.17 | Not disclosed |
DisclosureSEC source: 0001487371-21-000182 · wf-form4_161911413636920.xml · derivative · entry 3 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,062 shares Expires 2025-02-19 F4 · price: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof. Read SEC document |
| April 22, 2021 Filed Apr 22, 2021 13:55 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | OtherCommon Stock | 5,500 | $24.05 | $132,275.00 |
DisclosureSEC source: 0001487371-21-000182 · wf-form4_161911413636920.xml · nonDerivative · entry 2 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lisa M Giles Living Trust Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F3 · ownership.nature: Ms. Giles is the trustee of the Lisa M Giles Living Trust and has voting and dispositive power with respect to these shares. Ms. Giles disclaims beneficial ownership except to the extent of her pecuniary interest therein. Read SEC document |
| April 22, 2021 Filed Apr 22, 2021 13:55 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | OtherCommon Stock | 81,572 | $24.05 | $1,961,806.60 |
DisclosureSEC source: 0001487371-21-000182 · wf-form4_161911413636920.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F2 · shares: Includes 21,607 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 18:09 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 7,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-21-000049 · wf-form4_161377614019452.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,572 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2020 Equity Incentive Plan, which vest in full on June 1, 2022. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 22:01 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001209191-20-053839 · doc4.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2030-10-01 F1 · derivative.exercise_date: This option will vest in equal monthly installments, beginning on November 1, 2020, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 17:47 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 13,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-20-000191 · wf-form4_159113443734176.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,790 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2020 Equity Incentive Plan, which vest in full on the first anniversary of the grant date. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 16:49 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 528 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000224 · wf-form4_157264135683356.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,965 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan in connection with her appointment as Chair of the Compensation Committee of the Issuer's Board of Directors, which vest in full on the first anniversary of the grant date. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 17:20 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 702 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000170 · wf-form4_156478082472058.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,437 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan in connection with her appointment as a member of the Compensation Committee of the Issuer's Board of Directors, which vest in full on the first anniversary of the grant date. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 16:18 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 17,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000161 · wf-form4_155967946639986.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,735 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan, which vest in full on the first anniversary of the grant date. Read SEC document |
| May 24, 2018 Filed May 29, 2018 19:01 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 17,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-18-000126 · wf-form4_152763484727191.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,798 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan, which vest in full on the first anniversary of the grant date. Read SEC document |
| May 25, 2017 Filed May 30, 2017 18:41 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 6,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000125 · wf-form4_149618409366068.xml · nonDerivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,691 F1 · acquired: The amount reported reflects restricted stock units granted to the reporting person pursuant to the Issuer's 2010 Equity Incentive Plan, which vest in full on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.